David R. Bauer

Davis Polk advised the representatives of the underwriters in connection with the $75 million SEC-registered follow-on offering of 9,343,750 ordinary shares of Gamida Cell Ltd, which…

Davis Polk advised the underwriter in connection with the $340 million SEC-registered offering of 1,511,546 American depositary shares of BeiGene, Ltd. by certain existing ADS holders. The…

Davis Polk advised the sales agents on the SEC-registered at-the-market offering by RAPT Therapeutics, Inc. of its common stock for up to an aggregate amount of $100 million. RAPT…

Davis Polk advised the representatives of the several underwriters in connection with the initial public offering of 69,000,000 shares of Class A common stock of Maravai LifeSciences…

Davis Polk advised the representatives of the underwriters in connection with the $112 million public offering of 2,500,000 shares of common stock of Stoke Therapeutics, Inc., which…

Davis Polk advised the joint-bookrunning managers and representatives of the several underwriters in connection with an approximately $173.8 million public offering of common stock by…

Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market offering program by Affimed N.V. of up to $75 million gross sales price of…

Davis Polk is advising Novo Nordisk A/S on its $1.8 billion acquisition of Emisphere Technologies Inc. and related Eligen SNAC royalty stream obligations owed to MHR Fund Management LLC,…

Davis Polk advised the representatives of the underwriters in connection with the $345 million initial public offering of 14,375,000 shares of common stock of Atea Pharmaceuticals, Inc.,…

Davis Polk advised Coloplast on its acquisition of Nine Continents Medical, an early stage company pioneering an implantable tibial nerve stimulation treatment for over-active bladder. The…